The widespread use of highly active antiretroviral therapy (HAART) has had a significant impact on reducing the incidence of opportunistic infections in patients with the Acquired Immunodeficiency Syndrome (AIDS) and reducing the overall morbidity and mortality associated with this disease. However, the use of HAART is often associated with adverse effects, significant drug interactions, high cost and the emergence of viral resistance in a significant percentage of treatment recipients. In addition, the clinical efficacy of HAART in terms of viral eradication appears to be limited due to the presence of reservoirs of latent virus within HAART-experienced patients. Because of these and other limitations associated with antiretroviral therapies, new therapeutic strategies are being developed to restore the normal function of the immune system and improve patient outcomes. The purpose of this article is to review some of the more promising investigational immune-based therapies and their potential role in the management of Human Immunodeficiency Virus infection.
Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med. 1998; 338:853-860.
2.
Romerio F, Gallo RC. Novel biologic approaches for the treatment of AIDS. J Lab Clin Med. 1999; 134:577-584.
3.
Ho DJ, Dondero TJ, Rayfield MA, et al. The emerging genetic diversity of HIV—the importance of global surveillance for diagnostics, research and prevention. JAMA. 1996; 275:210-216.
4.
Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society—USA Panel. JAMA. 2000; 283:381-390.
5.
Wong JM, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278:1291-1295.
6.
Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278:1295-1300.
7.
Lederman MM. Host-directed and immune-based therapies for Human Immunodeficiency Virus Infection. Ann Intern Med. 1995; 122:218-221.
8.
Fauci AS, Pantaleo G, Stanley S, et al. Immunopathogenic Mechanisms of HIV infection. Ann Intern Med. 1996; 124:654-663.
9.
Lane HC, Depper JM, Greene WC, et al. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome; evidence for a selective defect in soluble antigen recognition. N Engl J Med. 1985; 313:79-84.
10.
Murray HW, Rubin BY, Masur H, et al. Impaired production of lymphokines and immune interferon in the acquired immunodeficiency syndrome. N Engl J Med. 1984; 310:883-889.
11.
Pantaleo G, Fauci AS. New concepts in the immunopathogenesis of HIV infection. Ann Rev Immunol. 1995; 13:487-512.
12.
Poli G, Fauci AS. Cytokine modulation of HIV expression. Semin Immunol. 1993; 5:165-173.
13.
Fauci AS. A multifactorial nature of HIV disease: implications for therapy. Science. 1993; 262:1011-1018.
14.
Lahdevirta J, Maury CP, Teppo AM, et al. Elevated levels of circulating cachectin/TNF in patients with acquired immunodeficiency syndrome. Am J Med. 1988; 85:289-291.
15.
Clerici M, Shearer GA. TH1-TH2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993; 14:1-7-110.
16.
Fan J, Bass HZ, Fahey JL. Elevated IFN-gamma and decreased IL-2 gene expression are associated with HIV-1 infection. J Immunolol. 1993; 262:1721-1724.
17.
Francis JL, Meltzer MS, Gendelman HE. Interferons in the persistence, pathogenesis and treatment of HIV infection. AIDS Res Hum Retroviruses. 1992; 2:199-237.
18.
Pantaleo G, Soudeyns H, Demarest JF, et al. Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary infection. Proc Natl Acad Sci. USA1997; 94:9848-9853.
19.
Lane HC, Masur H, Edgar LC, et al. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1983; 309:453-458.
20.
US Public Health Service and Infectious Diseases Society of America, 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with Human Immunodeficiency Virus. MMWR. 1999; 48(RR-10):1-65.
21.
Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1 specific CD4+ T cell responses associated with control of viremia. Science. 1997; 278:1447-1450.
22.
Autran B, Carcelain G, Li TS, et al. Restoration of the immune system with antiretroviral therapy. Immunol Let. 1999; 66:207-211.
23.
Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med. 1997; 3:533-540.
24.
Mitsuyasu RT. Immune reconstitution strategies in HIV infection. International AIDS Society—USA. 1999; 7:4-7.
25.
Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1 infected humans. Nat Med. 1999; 5:83-89.
26.
Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T-cell homeostasis and function in advanced HIV disease. Science. 1997; 277:12-16.
27.
Kaufmann D, Pantaleo G, Sudre P, et al. CD4-cell count in HIV-1-infected individuals remaining viremic with highly active antiretroviral therapy (HAART). Lancet. 1998; 351:723-724.
28.
Gorochov G, Neumann AU, Kreveur A, et al. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med. 1998; 4:208-214.
29.
Walker BD. The rationale for immunotherapy in HIV-1 infection. J Acquir Immune Defic Syndr. 1994; 7:s6-s13.
30.
Liebmann J, Huang X, Fan Z, et al. Highly active antiretroviral therapy (HAART) results in delayed enhancement of CD4+ T cell reactivity to mitogens and recall antigens but not HIV-1 antigens. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL. February 1-5, 1998. Abstract 169.
31.
Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine and ritonavir: results of AIDS ClinicalTrials Group protocol 315. J Infect Dis. 1998; 177:898-904.
32.
Notermans DW, Pakker NG, Hamann D, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated Human Immunodeficiency Virus Type 1-infected adults. J Infect Dis. 1999; 180:1050-1056.
33.
Li TS, Tubiana R, Katiama C, et al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly-active antiretroviral therapy in advanced HIV-1 disease. Lancet. 1998; 351:1682-1686.
34.
Pakker NG, Roos MTL, van Leeuwen R, et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immun Def Syn. 1997; 16:318-326.
35.
Rosenberg ES, Walker BD. HIV Type 1-specific helper T-cells improvement in control host defenses. AIDS Res Hum Retoviruses. 1998; 14(suppl 2):S143-S147.
36.
Rosenberg ES, Billingly JM, Caliendo AM, et al. Vigorous HIV-1 specific CD4+ T-cell responses associated with control of viremia. Science. 1997; 278:1447-1450.
37.
Smith KA, Interleukin-2: inception, impact, implications. Science. 1998; 240:1169-1176.
38.
Lucey DR, Elcher GP, Hendrix CW, et al. HIV infection in the U.S. Air Force: seroconversions, clinical staging, and assessment of a T-helper cell functional assay to predict change in CD4 T cell counts. J Infect Dis. 1991; 164:631-637.
39.
Coriali FP, Solomone M, Viora M, et al. Apoptosis in HIV infection: protective role of IL-2. J Biol Homest Agents. 1994; 8:60-64.
40.
Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients with the human immunodeficiency virus. N Engl J Med. 1996; 335:1350-1356.
41.
Carr A, Emery S, Lloyed A, et al. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. J Infect Dis. 1998; 178:992-999.
42.
Saravolatz L, Mitsuyasu R, Sneller M, et al. Duration of proleukin IL-2 therapy is more important than total dose in achieving CD4+ expansion (abstract 1149). Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996 Sep 15-18; New Orleans, LA.
43.
Davey RT, Chaitt D, Piscitelli SC, et al. Sub-cutaneous administration of IL-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis. 1997; 175:781-789.
44.
Hengge UR, Exner V, Esser S, et al. Randomized, controlled phase II trial of subcutaneous interleukin-2 in HIV patients (abstract 612). Abstracts of the 5th Conference on Retro-viruses and Opportunistic Infections; 1998 Feb 1-5; Chicago, IL.
45.
Levy Y, Capitant C, Houhou S, et al. IL-2 in HIV patients: a randomized trial comparing sc, PEG, CIV IL-2 with AZT + DDI. Abstracts of the 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, Switzerland.
46.
Arno A, Ruiz L, Juan M, et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with > 250/ml CD4+ T cells and undetectable plasma virus load. J Infect Dis. 1999; 180:56-60.
47.
Wood LV, Wiggington JM, Zuckerman J, et al. Pharmacokinetics, tolerance, and immunomodulatory activity of recombinant IL-2 in HIV-infected children and adolescents: results of a pilot study (abstract 222). Abstracts of the 5th Conference on Retro-viruses and Opportunistic Infections; 1998 Feb 1-5; Chicago, IL.
48.
Emery S, Capra W, Vig, et al. IL-2 therapy for HIV disease: a meta-analysis of three randomized, controlled trials (abstract 608). Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. 1998 Feb 1-5; Chicago, IL.
49.
Davey RT, Chaitt DG, Alberet JM, et al. A randomized controlled multicenter trial of subcutaneous interleukin-2 therapy in HIV infected patients with CD4+ counts of 200- 500 cells/ul (abstract 357). Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4, Chicago, IL.
50.
Davey RT, Chaitt DG, Alberet JM, et al. A randomized trial of high versus low dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis. 1999; 179:849-858.
51.
Losso M, Belloso W, Benetucci J, et al. Evaluation of subcutaneous interleukin-2 plus antiretroviral therapy versus antiretroviral therapy alone in patients with HIV-1 infection and CD4+ cell count > 350/mm3 (abstract 354). Abstracts of the 6th Conference on Retroviruses and Opportunistic Infection; 1999 Jan 31-Feb 4; Chicago, IL.
52.
Tambussi G, Magenta L, Nozza S, et al. Efficacy of a four arm controlled trial of antiviral and interleukin-2 in drug-experienced HIV-1 positive individuals with CD4+ counts of 200-500 cells/mm3 (abstract 355). Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections. 1999 Jan 31-Feb 4; Chicago, IL.
53.
Romanelli F.Interleukin-2 for the management of HIV infection. J Amer Pharm Ass. 1999; 39:967-968.
54.
James JS. IL-2 as low dose and treatment interruption: interview with Kendall A, Smith, M.D. AIDS Treatment News. 1999; 329:1-6.
55.
Jacobson EL, Pilaro F, Smith KA. Rational interleukin-2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA. 1996; 93:10405-10410.
56.
Bernstein ZP, Barresi G, Gould M, et al. A phase II study of daily subcutaneous low dose interleukin-2 in HIV-associated malignancies (abstract). J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 14:A40.
57.
Bernstein ZP, Porter MM, Gould M, et al. Prolonged administration of low-dose interleukin-2 in HIV-associated malignancy results in selective expansion of innate effects without significant clinical toxicity. Blood. 1995; 86:3287-3294.
58.
Sundin DJ, Wolin MJ. Toxicity management in patients receiving low-dose aldesleukin therapy. Ann Pharmacol. 1998; 32:1344-1352.
59.
Joint United Nations Program on HIV/AIDS (UNAIDS) [resource on World Wide Web]. Report on the global HIV/AIDS epidemic-June 2000. URL: http://www.unaids.org/epidemic_update/report/index.html. Accessed 2000, Aug 15.
60.
Grossman Z, Feinberg M, Kuznetsov V, et al. HIV infection: how effective is drug combination treatment?Immunol Today. 1998; 19:528-532.
61.
Pontesilli O, Guerra EC, Ammassari A, et al. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. AIDS. 1998; 12:473-480.
62.
Leandersson AC, Gilljam G, Fredriksson M, et al. Cross-reactive T-helper responses in patients infected with different subtypes of human immunodeficiency virus type 1. J Virol. 2000; 74(10):4888-4890.
63.
Gorse GJ, McElrath MJ, Matthews TJ, et al. Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. Vaccine. 1998; 16(5):493-506.
64.
Redfield RR, Birx DL, Ketter N, et al. A phase I evaluation of the safety and immunogenicity of vaccination with gp160 in patients with early human immunodeficiency virus infection. N Eng J Med. 1991; 324:1677-1684.
65.
Tsouka CM, Raboud J, Bernard NF, et al. Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelop subunit, on progression of immunodeficiency. AIDS Res Hum Retro-viruses. 1998; 14(6):483-490.
66.
AIDS Clinical Trial Information Service (ACTIS) [Resource on the World Wide Web]. URL: http://www.actis.org. Accessed 2000 Aug 15.
67.
Agouron Pharmaceuticals [Resource on the World Wide Web]. URL: http://www.agouram.com. Accessed 2000 Aug 15.
68.
Moss RB, Wallace MR, Giermakowska WK, et al. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen. J Infec Dis. 1999; 180:641-648.
69.
Moss RB, Trauger RJ, Giermakowska WK, et al. Effect in immunization with an inactivated gp120-depleted HIV-1 immunogen on β-chemokine and cytokine production in subjects with HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 14(4):343-350.
70.
Moss RB, Li L, Giermakowska WK, et al. Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with gp120-depleted, inactivated HIV-1 in incomplete Freund’s adjuvant (Remune) in HIV-1-seropositive subjects. J Hum Virol. 1998; 1(2):77-81.
71.
Aukrust P, Liabakk NB, Muller F, et al. Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection—correlations to clinical, immunologic, and virologic parameters. J Infec Dis. 1994; 169(2):420-424.
72.
Rizzardi GP, Barcellini W, Tambussi G, et al. Plasma levels of soluble CD30, tumor necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome. AIDS. 1996; 10(13):F45-F50.
73.
Maino VC, Suni MA, Wormsley SB, et al. Enhancement of HIV type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen. AIDS Res Hum Retroviruses. 2000; 16(6):539-547.
74.
Churdboonchart V, Moss RB, Sirawaraporn W, et al. Effect of HIV-specific immune-based therapy in subjects with HIV-1 subtype E in Thailand. AIDS. 1998; 12:1521-1527.
75.
Moss RB, Giermakowska WK, Lanza P, et al. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund’s adjuvant (HIV-1 immunogen, Remune) in human immunodeficiency virus type-1 sero-positive patients. Viral Immunol. 1997; 10(4):221-228.
76.
Patterson BK, Carlo DJ, Kaplan MH, et al. Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen. AIDS. 1999; 13:1607-1611.
77.
Limsuwan A, Churdboonchart V, Moss RB, et al. Safety and immunogenicity of Remune in HIV-infected Thai subjects. Vaccine. 1998; 16(2/3):142-149.
78.
AIDS Clinical Trial Information Service (ACTIS) [Resource on the World Wide Web]. A randomized, double-blind, adjuvant-controlled, multicenter study to compare the virologic and immunologic effect of highly active antiretroviral therapy (HAART) plus Remune versus HAART plus incomplete Freund’s adjuvant (IFA) in antiretroviral-naive patients infected with human immunodeficiency virus type 1 (HIV-1). URL: http://www.actis.org. Accessed 2000 Aug 15.
79.
AIDS Clinical Trial Information Service (ACTIS) [Resource on the World Wide Web]. A multicenter, double-blind, phase III, adjuvant-controlled study of the effect of 10 units of HIV-1 immunogen (Remune) compared to incomplete Freund’s adjuvant (IFA) alone every 12 weeks on AIDS-free survival in subjects with HIV infection and CD4 T-lymphocytes between 300 and 549 cells/microL regardless of concomitant HIV therapies). URL: http://www.actis.org. Accessed 2000 Aug 15.
80.
AIDS Clinical Trial Information Service (ACTIS). Phase I study to evaluate the safety and immunogenicity of HIV-1 immunogen in children with HIV-1 infection. URL: http://www.actis.org. Accessed August 15, 2000.
81.
Gringeri A, Musicco M, Hermans P, et al. Active anti-interferon-alpha immunization: a European-Israli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1-infected patients (the EURIS Study). J Acquired Immun Def Synd. 1999; 20:358-370.
82.
Francis ML, Meltzer MS, Gendelman HE. Interferons in the persistence, pathogenesis and treatment of HIV infection. AIDS Res Hum Retroviruses. 1992; 2:199-237.
83.
Gringeri A, Santagostino E, Mannucci PM, et al. A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization. J Acqur Immune Defic Syndr. 1994; 7:978-988.
84.
Gringeri A, Santagostino E, Cusini M, et al. Absence of clinical, virological and immunological signs of progression in HIV-1 infected patients receiving active anti-interferon immunization: a 30-month follow up. J Acquir Immune Defic Syndr Hum Retrovirol. 1996; 41:381-388.
85.
Neoral package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 1998 Mar.
86.
Brinkman K, Huysmans F, Burger D.Pharmacokinetic interaction between saquinavir and cyclosporine. Ann Int Med. 1998; 129(11):914-915.
87.
Smak Gregoor PJH, Van Gelder T, Van Der Ende ME, et al. Cyclosporine and triple-drug treatment with human immunodeficiency virus protease inhibitors. Transplantation. 1999; 68(8):1210-1211.
88.
Franke EK, Luban J.Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology. 1996; 222(1):279-282.
89.
Bell KD, Ramilo O, Vitetta ES. Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus. Proc Natl Acad Sci USA. 1993; 90(4):1411-1415.
90.
Schwarz A, Offermann G, Keller F, et al. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation—data on four cases and a review of the literature. Transplantation. 1993; 55(1):95-103.
91.
Weber J, Galpin S.Cyclosporin A. Nature. 1995; 375(6528):198.
92.
Levy R, Jais JP, Tourani JM, et al. Long-term follow-up of HIV positive asymptomatic patients having received cyclosporine A. Adv Exp Med Biol. 1995; 374:229-234.
93.
Aboulker JP, Andrieu JM, Gastaud JA. Two month double blind placebo controlled trial of cyclosporine in HIV asymptomatic subjects. Int Conf AIDS. 1989, Jun 4-9; 5:402 (ab).
94.
AIDS Clinical Trial Information Service (ACTIS). Phase II study of cyclosporine (Neoral) in immune activation and HIV expression in early HIV disease. URL: http://www.actis.org. Accessed August 16, 2000.
Shannon E, Aseffa A, Pankey G, et al. Thalidomide’s ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+ cells in their blood. Immunopharmacology. 2000; 46(2):175-179.
97.
Haslett PA, Klausner JD, Makonkawkeyoon S, et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retro-viruses. 1999; 15(13):1169-1179.
98.
Bekker LG, Haslett P, Maartens G, et al. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. J Infec Dis. 2000; 181:954-965.
99.
Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS1996; 10(13):1501-1507.
100.
Sharpstone D, Rowbottom A, Francis N, et al. Thalidomide: a novel therapy for microsporidiosis. Gastroenterology. 1997; 112(6):1823-1829.
101.
Jacobson JM, Spritzler J, Fox L, et al. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. J Infec Dis. 1999; 180(1):61-67.
102.
Ramirez-Amador VA, Esquivel-Pedraza L, Ponce-de-Leon S, et al. Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial. Clin Infect Dis. 1999; 28(4):892-894.
103.
Fife K, Howard MR, Gracie F, et al. Activity of thalidomide in AIDS-related Kaposi’s sarcoma and correlation with HHV8 titer. Int J STD AIDS. 1998; 9(12):751-755.
104.
Marriott JB, Cookson S, Carlin E, et al. A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. AIDS Res Hum Retroviruses. 1997; 13(18):1625-1631.
105.
Haslett P, Tramontana J, Burroughs M, et al. Adverse reactions to thalidomide in patients infected with human immunodeficiency virus. Clin Infec Dis. 1997;24(6):1223-1227.
106.
Trental package insert. Kansas City, MO: Hoechst-Roussel Pharmaceuticals; Jan 1998.
107.
Navarro J, Punzon MC, Pizarro A, et al. Pentoxifylline inhibits acute HIV-1 replication in human T cells by a mechanism not involving inhibition on tumor necrosis factor synthesis or nuclear factor-kappa B activation. AIDS. 1996; 10(5):469-475.
108.
Clerici M, Piconi S, Balotta C, et al. Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons. J Infec Dis. 1997; 175(5):1210-1215.
109.
Dezube BJ, Lederman MM, Spritzler JG, et al. High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. J Infec Dis. 1995; 171(6):1628-1632.
110.
Wallis RS, Nsubuga P, Whalen C, et al. Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial. J Infec Dis. 1996; 174(4):727-733.
111.
Berman B, Flores F, Burke G.Efficacy of pentoxifylline in the treatment of pruretic papular eruption of HIV-infected persons. J Am Acad Dermatol. 1998; 38(6):955-959.
112.
Intron A package insert. Kenilworth, NJ: Schering Corporation; Mar 1998.
